- Home
- BLFS vs VTYX Comparison
BLFS vs VTYX Comparison
Compare BLFS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | VTYX |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 990.9M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLFS | VTYX |
|---|---|---|
| Price | $20.63 | $13.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 7 |
| Target Price | ★ $32.00 | $13.50 |
| AVG Volume (30 Days) | 436.8K | ★ 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,214,000.00 | N/A |
| Revenue This Year | $19.20 | N/A |
| Revenue Next Year | $18.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $19.15 | $0.90 |
| 52 Week High | $29.57 | $15.34 |
Technical Indicators
Market Signals| Indicator | BLFS | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 72.58 |
| Support Level | $20.54 | $13.89 |
| Resistance Level | $23.00 | $14.07 |
| Average True Range (ATR) | 1.03 | 0.03 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 18.94 | 88.89 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.